News Releases

Date Title
05/12/2014 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel
05/08/2014 Summary ToggleEnanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
04/30/2014 Summary ToggleEnanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference
04/28/2014 Summary ToggleEnanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six Months Ended March 31, 2014
04/22/2014 Summary ToggleEnanta Pharmaceuticals Announces New Drug Application Submission to the U.S. FDA for All-Oral, Interferon-Free Hepatitis C Regimen
04/12/2014 Summary ToggleEnanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting
04/11/2014 Summary ToggleEnanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting
03/24/2014 Summary ToggleEnanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting
03/04/2014 Summary ToggleEnanta Pharmaceuticals Announces New Data Presented on Protease Inhibitor ABT-493 at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)
03/03/2014 Summary TogglePEARL-III Study Results in Patients with Chronic Hepatitis C Presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)